[{"data":1,"prerenderedAt":-1},["ShallowReactive",2],{"doc-seo-351731-105":3,"detail-sidebar-cat-0-en-105":85,"doc-detail-351731-en":134},{"code":4,"msg":5,"data":6},0,"ok",{"site_id":7,"language":8,"slug":9,"title":10,"keywords":11,"description":12,"schema_data":13,"social_meta":78,"head_meta":80,"extra_data":82,"updated_unix":84},105,"en","circulating-plasma-mirna-548l-as-novel-predictive-biomarker-of-radiotherapy-induced-severe-oral-mucositis-in-patients-with-laryngeal-cancer","Circulating Plasma miRNA-548L as Novel Predictive Biomarker of Radiotherapy-Induced Severe Oral Mucositis in Patients with Laryngeal Cancer","","Oral mucositis (OM) is a frequent, debilitating complication of radiotherapy in laryngeal cancer, and accurate prediction of severity is essential for timely intervention. This retrospective study evaluates plasma miRNA-548L in 76 patients receiving radiotherapy, analyzing miRNA expression and related molecular pathways. Lower miRNA-548L levels were observed in patients developing severe OM across multiple radiotherapy cycles, with good week-specific discrimination (AUC 0.77–0.86). Reduced expression also correlated with shorter overall survival.",{"@graph":14,"@context":77},[15,34,56],{"@type":16,"itemListElement":17},"BreadcrumbList",[18,23,27,31],{"item":19,"name":20,"@type":21,"position":22},"https://docshare.wps.com","Home","ListItem",1,{"item":24,"name":25,"@type":21,"position":26},"https://docshare.wps.com/document/","Document",2,{"item":28,"name":29,"@type":21,"position":30},"https://docshare.wps.com/document/research-report/","Research & Report",3,{"item":32,"name":10,"@type":21,"position":33},"https://docshare.wps.com/document/circulating-plasma-mirna-548l-as-novel-predictive-biomarker-of-radiotherapy-induced-severe-oral-mucositis-in-patients-with-laryngeal-cancer/351731/",4,{"url":32,"name":10,"@type":35,"image":36,"author":41,"headline":10,"publisher":44,"fileFormat":47,"inLanguage":8,"description":12,"dateModified":48,"datePublished":49,"encodingFormat":47,"isAccessibleForFree":50,"interactionStatistic":51},"DigitalDocument",{"url":37,"@type":38,"width":39,"height":40},"https://docshare.wps.com/thumbnails/circulating-plasma-mirna-548l-as-novel-predictive-biomarker-of-radiotherapy-induced-severe-oral-mucositis-in-patients-with-laryngeal-cancer/351731.png","ImageObject",300,407,{"name":42,"@type":43},"McQueen","Person",{"url":19,"name":45,"@type":46},"DocShare","Organization","application/pdf","2026-11-13","2026-09-22",true,{"@type":52,"interactionType":53,"userInteractionCount":55},"InteractionCounter",{"@type":54},"ViewAction",7,{"@type":57,"mainEntity":58},"FAQPage",[59,65,69,73],{"name":60,"@type":61,"acceptedAnswer":62},"What is the main purpose of the study?","Question",{"text":63,"@type":64},"To evaluate whether pretreatment plasma miRNA-548L can predict the occurrence and severity of oral mucositis in laryngeal cancer patients undergoing radiotherapy.","Answer",{"name":66,"@type":61,"acceptedAnswer":67},"How was miRNA-548L assessed in the patients?",{"text":68,"@type":64},"Plasma miRNA expression levels were measured in samples collected from 76 laryngeal cancer patients before starting radiotherapy, and bioinformatics analyses were used to explore related molecular pathways.",{"name":70,"@type":61,"acceptedAnswer":71},"What relationship was found between miRNA-548L levels and severe oral mucositis?",{"text":72,"@type":64},"Patients who developed severe oral mucositis after specific radiotherapy cycles showed significantly decreased miRNA-548L levels, and miRNA-548L helped differentiate severe OM development during several treatment weeks.",{"name":74,"@type":61,"acceptedAnswer":75},"Did miRNA-548L expression influence overall survival?",{"text":76,"@type":64},"Yes. Lower miRNA-548L expression was significantly associated with shorter median overall survival.","https://schema.org",{"og:url":32,"og:type":79,"og:title":10,"og:site_name":45,"og:description":12},"article",{"robots":81,"canonical":32},"index,follow",{"doc_id":83,"site_id":7},351731,1790720976,{"code":4,"msg":86,"data":87},"success",[88,92,96,100,105,110,114,118,123,126,130],{"id":22,"doc_module":4,"doc_module_name":25,"category_name":89,"show_sort_weight":90,"slug":91},"Story & Novel",90,"story-novel",{"id":26,"doc_module":4,"doc_module_name":25,"category_name":93,"show_sort_weight":94,"slug":95},"Literature",80,"literature",{"id":33,"doc_module":4,"doc_module_name":25,"category_name":97,"show_sort_weight":98,"slug":99},"Exam",70,"exam",{"id":101,"doc_module":4,"doc_module_name":25,"category_name":102,"show_sort_weight":103,"slug":104},5,"Comic",60,"comic",{"id":106,"doc_module":4,"doc_module_name":25,"category_name":107,"show_sort_weight":108,"slug":109},6,"Technology",50,"technology",{"id":55,"doc_module":4,"doc_module_name":25,"category_name":111,"show_sort_weight":112,"slug":113},"Healthcare",40,"healthcare",{"id":115,"doc_module":4,"doc_module_name":25,"category_name":29,"show_sort_weight":116,"slug":117},8,30,"research-report",{"id":119,"doc_module":4,"doc_module_name":25,"category_name":120,"show_sort_weight":121,"slug":122},9,"Religion & Spirituality",20,"religion-spirituality",{"id":121,"doc_module":4,"doc_module_name":25,"category_name":124,"show_sort_weight":121,"slug":125},"World Cup","world-cup",{"id":127,"doc_module":4,"doc_module_name":25,"category_name":128,"show_sort_weight":127,"slug":129},10,"Lifestyle","lifestyle",{"id":131,"doc_module":4,"doc_module_name":25,"category_name":132,"show_sort_weight":101,"slug":133},19,"General","general",{"code":4,"msg":86,"data":135},{"doc_id":83,"user_id":136,"nickname":42,"user_avatar":137,"doc_module":4,"category_id":115,"category_name":29,"doc_title":10,"doc_description":12,"doc_content":138,"file_id":139,"file_url":140,"file_type":141,"file_size":142,"view_count":55,"is_deleted":4,"is_public":22,"is_downloadable":22,"audit_status":22,"page_count":143,"language":144,"language_code":8,"site_id":7,"html_lang":8,"table_of_contents":145,"faqs":146,"seo_title":147,"seo_description":12,"update_tm":148,"read_time":149,"preview_page_count":33,"preview_urls":150},5909890329169,"https://ap-avatar.wpscdn.com/davatar_9964176cb1d06d4a9deccf72a44ae3dc","Article  \nCirculating Plasma miRNA-548L as Novel Predictive Biomarker of Radiotherapy-Induced Severe Oral Mucositis in Patients with Laryngeal Cancer  \nMarcin Mazurek 1, *, Anna Brzozowska 2, Teresa Małecka-Massalska 1 and Tomasz Powrózek 1, *  \nAcademic Editor: Zihua Hu  \nReceived: 21 April 2026  \nRevised: 7 May 2026  \nAccepted: 16 May 2026  \nPublished: 18 May 2026  \nCopyright: © 2026 by the authors. Licensee MDPI, Basel, Switzerland. This article is an open access article distributed under the terms and conditions of the Creative Commons Attribution (CC BY) license.  \n1 Department of Human Physiology of the Chair of Preclinical Sciences, Medical University of Lublin, 20-080 Lublin, Poland  \n2 Department of Radiotherapy, St. John of Dukla Lublin Region Cancer Center, 20-090 Lublin, Poland  \n* [Correspondence: marcinmazurek1@umlub.edu.pl](Correspondence: marcinmazurek1@umlub.edu.pl) (M.M.); [tomaszpowrozek@gmail.com](tomaszpowrozek@gmail.com) (T.P.)  \nAbstract  \nBackground/Objectives: Oral mucositis (OM) is a common complication in laryngeal cancer (LC), during radiotherapy (RT), significantly affecting patient outcomes. Identifying sensitive biomarkers to predict OM severity is therefore crucial. MicroRNAs, which regulate inflammatory pathways involved in OM, are promising candidates. This retrospective study aimed to evaluate plasma miRNA-548L as a predictive biomarker for the occurrence and severity of OM in LC patients undergoing RT. Methods: The expression levels of the selected miRNAs were analyzed in plasma samples obtained from 76 LC patients prior to the initiation of RT. Bioinformatics analyses were performed to identify molecular pathways regulated by miRNA-548L and their potential link to the pathogenesis of OM. Results: Significantly decreased levels of the studied miRNA were observed in the plasma of LC patients who developed severe OM after the IVth (p \u003C 0 .001), Vth (p = 0 .039), VIth (p \u003C 0 .001), and VII th (p \u003C 0 .001) cycles of RT. Additionally, the expression of miRNA-548L enabled reliable differentiation between patients who developed severe OM during the IVth (AUC = 0 .81, p \u003C 0 .001), Vth (AUC = 0 .77, p \u003C 0 .001), VIth (AUC = 0 .82, p \u003C 0 .001), and VII th (AUC = 0.86, p \u003C 0.001) weeks of treatment. Importantly, lower expression of miRNA-548L (HR = 3.12; p = 0.010) was significantly associated with shorter median overall survival (OS) . Conclusions: Pretreatment plasma miRNA-548L shows potential as a biomarker for predicting severe OM in LC patients undergoing RT. Notably, reduced miRNA-548L expression is associated with shorter OS and may help stratify patients by OM severity.  \nKeywords: laryngeal cancer; oral mucositis; miRNA-548L; radiotherapy  \n1. Introduction  \nAmong head and neck cancers (HNCs), laryngeal carcinoma (LC) represents the most prevalent malignancy, accounting for approximately 30–40% of all HNC cases. LC primarily arises from the epithelial lining of the laryngeal mucosa and is strongly associated with prolonged exposure to carcinogenic agents [1,2] . Major etiological factors include tobacco smoking, excessive alcohol consumption, and infection with high-risk human papillomavirus (HPV) strains [3] . More than 90% of LCs originate from the mucosal epithelium, with well-differentiated squamous cell carcinoma constituting the predominant histopathological subtype [4] .  \nRadiotherapy (RT) is used in approximately 75% of HNC cases and is frequently administered in combination with other therapeutic modalities, including surgery and  \nchemotherapy (CTH) . Despite its clinical efficacy, RT particularly when combined with CTH can induce damage to both malignant and normal tissues, with the highly radiosensitive mucosal lining of the oral cavity and pharynx being especially vulnerable. This tissue injury commonly results in oral mucositis (OM), a prevalent and debilitating complication of irradiation [5] . OM typically manifests within 2–4 weeks following the initiation of RT and may persi","cbCaifDpMH9cPUQk","https://ap.wps.com/l/cbCaifDpMH9cPUQk","pdf",1544417,14,"English","# Introduction\n## Rationale for biomarkers in OM prediction\n## Radiation-driven inflammatory mechanisms","[{\"question\":\"What is the main purpose of the study?\",\"answer\":\"To evaluate whether pretreatment plasma miRNA-548L can predict the occurrence and severity of oral mucositis in laryngeal cancer patients undergoing radiotherapy.\"},{\"question\":\"How was miRNA-548L assessed in the patients?\",\"answer\":\"Plasma miRNA expression levels were measured in samples collected from 76 laryngeal cancer patients before starting radiotherapy, and bioinformatics analyses were used to explore related molecular pathways.\"},{\"question\":\"What relationship was found between miRNA-548L levels and severe oral mucositis?\",\"answer\":\"Patients who developed severe oral mucositis after specific radiotherapy cycles showed significantly decreased miRNA-548L levels, and miRNA-548L helped differentiate severe OM development during several treatment weeks.\"},{\"question\":\"Did miRNA-548L expression influence overall survival?\",\"answer\":\"Yes. Lower miRNA-548L expression was significantly associated with shorter median overall survival.\"}]","Circulating Plasma miRNA-548L as Novel Predictive Biomarker of Radiotherapy-Induced Severe Oral Mucositis in Patients with Laryngeal Cancer | PDF",1790095549,35,[151,155,159,163],{"page_no":22,"url":152,"width":153,"height":154},"https://res-academy.cache.wpscdn.com/upload/kdocshare/2026-11-16/288847dadbe81bd083949900a6ff14fb.webp",983,1390,{"page_no":26,"url":156,"width":157,"height":158},"https://res-academy.cache.wpscdn.com/upload/kdocshare/2026-11-16/c12c19cac8955286a8fb0207e58463a2.webp",982,1388,{"page_no":30,"url":160,"width":161,"height":162},"https://res-academy.cache.wpscdn.com/upload/kdocshare/2026-11-16/9ae58a84b2e6ee1b9bf45d242f8d9343.webp",981,1387,{"page_no":33,"url":164,"width":165,"height":166},"https://res-academy.cache.wpscdn.com/upload/kdocshare/2026-11-16/4a2f67c3b89003924165430257dfeac3.webp",980,1385]